TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26595
Abstract: Long‐term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53‐altered chronic lymphocytic leukemia (CLL); however, it is unknown how… read more here.
Keywords: tp53 altered; bruton tyrosine; inhibitor; kinase inhibitor ... See more keywords
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5787
Abstract: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect… read more here.
Keywords: plus tyrosine; kinase inhibitor; immunotherapy plus; tyrosine kinase ... See more keywords
Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1186
Abstract: Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy subjects to determine the absorption, distribution, metabolism, and excretion of pexidartinib… read more here.
Keywords: kinase inhibitor; pexidartinib; mass balance; dose proportionality ... See more keywords
Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1238
Abstract: Famitinib is a tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors. Here, a 3‐period crossover trial investigated the effect of high‐fat or low‐fat food intake on the single‐dose pharmacokinetic properties of… read more here.
Keywords: chinese participants; kinase inhibitor; tyrosine kinase; intake ... See more keywords
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.853
Abstract: Ribociclib, a selective and potent cyclin‐dependent kinase 4/6 inhibitor, has demonstrated safety and efficacy in combination with endocrine therapy in hormone receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer. In 2 open‐label crossover studies… read more here.
Keywords: bioequivalence; cyclin dependent; bioavailability; kinase inhibitor ... See more keywords
Identification of preoperative factors associated with outcomes following surgical management of intra‐abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24988
Abstract: The role of surgical resection in the treatment of patients with metastatic/recurrent gastrointestinal stromal tumors (GIST) is unclear. The aim of this study was to identify preoperative factors associated with oncologic outcomes for recurrent/metastatic GIST… read more here.
Keywords: recurrent metastatic; preoperative factors; factors associated; kinase inhibitor ... See more keywords
Gene polymorphisms of cyclin‐dependent kinase inhibitor and matrix metalloproteinase‐9 in Sudanese patients with esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Genetics & Genomic Medicine"
DOI: 10.1002/mgg3.2074
Abstract: The polymorphisms of the cyclin‐dependent kinase inhibitor (CDKN1A) gene and matrix metalloproteinase‐9 (MMP9) gene may increase one's susceptibility to malignancies. In this study, the association of the single nucleotide polymorphisms (SNPs) CDKN1A rs1059234 c.70C>T at… read more here.
Keywords: dependent kinase; cyclin dependent; kinase inhibitor; gene ... See more keywords
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04779-x
Abstract: Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI… read more here.
Keywords: tyrosine kinase; kinase inhibitor; discontinuation; tki ... See more keywords
The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04040-0
Abstract: Purpose Lapatinib is a small molecule tyrosine kinase inhibitor used to treat breast cancer, often in combination with chemotherapy. Diarrhoea commonly occurs in up to 78% of patients undertaking lapatinib treatment. The mechanism of this… read more here.
Keywords: glp analogue; kinase inhibitor; lapatinib; diarrhoea caused ... See more keywords
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02910-6
Abstract: PurposeThe advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) recommends quantification of BCR–ABL1 transcripts by real-time quantitative PCR every 3 months during TKI treatment.… read more here.
Keywords: response; molecular response; deep molecular; kinase inhibitor ... See more keywords
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00925-2
Abstract: Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We… read more here.
Keywords: relapsed refractory; kinase inhibitor; refractory nasopharyngeal; nasopharyngeal carcinoma ... See more keywords